Actively Recruiting
Phase 2 Study of Surgery With or Without Apalutamide and Androgen Deprivation Therapy in Men With High-Risk Oligometastatic Prostate Cancer Using PSMA PET Imaging
Led by Marco Oderda · Updated on 2025-01-06
94
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating adjuvant treatments in men with high-risk prostate cancer who are candidates for radical prostatectomy with pelvic lymph node dissection. This phase 2 study focuses on patients staged as oligometastatic using PSMA PETCT imaging despite showing no metastases on conventional imaging. The goal is to compare outcomes between apalutamide plus androgen deprivation therapy ADT versus ADT alone after surgery. Participants will be randomly assigned to receive either apalutamide combined with ADT or ADT alone, starting about 4 weeks after surgery. ADT involves medical castration using gonadotropin-releasing hormone analogues. PSA and testosterone levels will be measured before starting treatment and every 3 months afterward. A PSMA PETCT scan will be done yearly or if PSA levels indicate progression. After 18 months of therapy, a 6-month follow-up phase will occur before study completion. During the study, participants will attend regular clinical visits for blood tests and imaging to monitor treatment response and side effects. Researchers will assess radiological progression-free survival up to 24 months from randomization as the main outcome. Adverse events will also be tracked throughout the study period. After study completion, patients will continue their follow-up according to best clinical practice.
CONDITIONS
Brief Title
Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PET
Research Team
M
Marco Oderda, MD, PhD
G
Giorgio Calleris, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here